PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY – 30 JUNE 2025)
Link to PDF here.
MEET US AT:
[November 17, 2025]
Dansk Aktionærforening “Investordagen 2025”.
More information and registration at the link here.
[November 24, 2025]
AktieInfo Aalborg.
More information and registration at the link here.
[November 25, 2025]
Aktielnfo Kolding.
More information and registration at the link here.
[November 26, 2025]
Økonomisk Ugebrev Life Science.
More information and registration at the link here.
[November 27, 2025]
Aktiespararna Stora Aktiedagarna
More information and registration at the link here
[January 12–14, 2026]
Biotech Showcase, JP Morgan Healthcare Week, San Francisco, United States.
More information and registration at the link here
On the business / CEO’s message:
Business Update – CEO Gustav H. Gram comments new Obesity study agreement with Gubra [October 02, 2025]
Clinical stage biotech company PILA PHARMA has entered into an agreement with the Danish research organisation Gubra to conduct preclinical studies of the their drug candidate, a TRPV1 inhibitor called XEN-D0501, in obesity. The studies aim to show proof-of-concept in obesity rat models and constitute an important step in the company’s development of this innovative treatment as a potential next generation, oral, first-in-class drug candidate. In an interview with Direkt Studios, CEO Gustav H. Gram comments on the significance of the agreement and the next step in the research program.
Link to video here
Oversubscribed to 293,5%! CEO reacts and discusses rights issue outcome with 10X Podcast! [August 29, 2025]
Among other topics the following is discussed: the heavily oversubscribed rights issue (293,5%), How it fuels our aspirations to investigate our proprietary and potential first-in-class TRPV1 inhibitor, in pure obesity studies, The timelines with which investors can expect news. Furthermore its debated how the obesity market is a theme, how it has become a megatrend, with an expected future fragmenting market with emphasis on tablets to address the market volume. Subsequently to conclude how a company like PILA PHARMA‘s and its simple oral alternative solution fits in the big picture
The podcast segment is recorded in English and the segment starts at 29:40
Link to video here
Online H1 report presentation & Q&A with Direkt Studios [August 27, 2025]
Pila Pharma CEO Gustav H. Gram is Interviewed about the Half-Year Report as well as the results of the Rights Issue. Interviewer: Joakim Båge.
Link to video here
SIT-DOWN INTERVIEW WITH FINWIRE TALKING FUNDRAISING AND BET ON OBESITY [July 04, 2025]
CEO Gustav H. Gram begins by introducing the PILA PHARMA ‘oral solution for obesity, a TRPV1-antagonist, a very different target to other drugs in development for obesity and diabetes. He emphasizes how the obesity market has grown tremendously and is increasingly looking to fragment and how oral solutions will be key to address the huge volume of people living with overweight globally.
He also talks about their ongoing rights issue of units, where the company wish to fund dedicated obesity studies in rats and humans living with overweight. With the issue quite remarkably covered by pre-commitments to 99,87%, and why PILA PHARMA may present an attractive opportunity for investors in a market segment with estimates of more than 1 billion people living with obesity and value estimates of more than $100 billion annually by 2030.
Find the link to the video (In English) here
On the mechanism / Founders word:
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram.
Find the link to the video (In Danish) here
Obesity and diabetes are serious global health challenges.
In this interview with SVT (Swedish national public television broadcaster), Dorte shares her unique approach to tackling these issues—with the help of chili.
Watch and read the full article here to learn more about her vision and the science behind it (in Swedish).
We were incredibly honoured that the American Diabetes Association(ADA) featured PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.
In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes.
Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our previous CEO explain!
Watch the video (in English) here
